<p>Results of published studies on the combination of carboplatin and paclitaxel in patients with metastatic melanoma.</p
In this brief report, we present our experience with 3-weekly paclitaxel-carboplatin chemotherapy fo...
BACKGROUND: This Phase II multicenter study evaluated the efficacy and toxicity of paclitaxel (200 m...
Purpose: Elesclomol, an investigational first-in-class compound, induces oxidative stress, triggers ...
BACKGROUND: Patients with metastatic melanoma have a very unfavorable prognosis with few therapeutic...
Patients with metastatic melanoma have a very unfavorable prognosis with few therapeutic options. Ba...
Combination of paclitaxel and carboplatin as second‐line therapy for patients with metastatic melano...
Background Taxanes are a mainstay in the treatment of metastatic breast cancer (mBC). Combination ch...
<p><b>Copyright information:</b></p><p>Taken from "Results of paclitaxel (day 1 and 8) and carboplat...
<p><b>Copyright information:</b></p><p>Taken from "Results of paclitaxel (day 1 and 8) and carboplat...
There is no standard second-line regimen for malignant melanoma patients with disease progression af...
The aim of this study was to investigate the activity and safety of a regimen containing carboplatin...
Background: The combination of paclitaxel and carboplatin has been used to treat patients with many ...
To investigate the addition of prophylactic G-CSF to each weekly paclitaxel/carboplatin course in pa...
Purpose: The primary objective of this study was to determine whether carboplatin, paclitaxel, and s...
The combination of carboplatin and paclitaxel given every three weeks is a tolerated and reasonably ...
In this brief report, we present our experience with 3-weekly paclitaxel-carboplatin chemotherapy fo...
BACKGROUND: This Phase II multicenter study evaluated the efficacy and toxicity of paclitaxel (200 m...
Purpose: Elesclomol, an investigational first-in-class compound, induces oxidative stress, triggers ...
BACKGROUND: Patients with metastatic melanoma have a very unfavorable prognosis with few therapeutic...
Patients with metastatic melanoma have a very unfavorable prognosis with few therapeutic options. Ba...
Combination of paclitaxel and carboplatin as second‐line therapy for patients with metastatic melano...
Background Taxanes are a mainstay in the treatment of metastatic breast cancer (mBC). Combination ch...
<p><b>Copyright information:</b></p><p>Taken from "Results of paclitaxel (day 1 and 8) and carboplat...
<p><b>Copyright information:</b></p><p>Taken from "Results of paclitaxel (day 1 and 8) and carboplat...
There is no standard second-line regimen for malignant melanoma patients with disease progression af...
The aim of this study was to investigate the activity and safety of a regimen containing carboplatin...
Background: The combination of paclitaxel and carboplatin has been used to treat patients with many ...
To investigate the addition of prophylactic G-CSF to each weekly paclitaxel/carboplatin course in pa...
Purpose: The primary objective of this study was to determine whether carboplatin, paclitaxel, and s...
The combination of carboplatin and paclitaxel given every three weeks is a tolerated and reasonably ...
In this brief report, we present our experience with 3-weekly paclitaxel-carboplatin chemotherapy fo...
BACKGROUND: This Phase II multicenter study evaluated the efficacy and toxicity of paclitaxel (200 m...
Purpose: Elesclomol, an investigational first-in-class compound, induces oxidative stress, triggers ...
DOI
Add to ORKG